The Pharmacy Times® Asthma resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
May 31 Pharmacy Week in Review: American Society of Clinical Oncology Meeting Coverage Coming, Behaviors and Psychosocial Stressors May Increase Asthma Risk in Adolescents
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
The new phase 2 data for an investigational once-daily, fixed dose combination currently in development for the treatment of inadequately controlled asthma was presented at the 2019 Annual International Congress of the American Thoracic Society (ATS) in Dallas.
Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.
Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.
Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.
Previous research has found illicit opiates may exacerbate asthma.
Inhaler misuse may result in more asthma attacks.
Some may remember the old formulation of OTC Primatene Mist that was taken off the market in 2011 because it contained chlorofluorocarbon (CFC) propellants, which are known to deplete the ozone layer.
The FDA announced approval of Wixela Inhub on January 30, 2019.
Pulmatrix is set to launch a clinical investigation on the product in 2019.
With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.